The following table presents the Company’s current pipeline: | | | | | | | | | | | | Therapeutic Area | Name | Stage | Product Rights | Cardiometabolic | ARO-APOC3 | Phase 2b and Phase 3 | Arrowhead | | ARO-ANG3 | Phase 2b | Arrowhead | | Olpasiran | Phase 3 | Amgen | Pulmonary | ARO-ENAC2 | Pre-Clinical | Arrowhead | | ARO-RAGE | Phase 1/2 | Arrowhead | | ARO-MUC5AC | Phase 1/2a | Arrowhead | | ARO-MMP7 | Phase 1/2a | Arrowhead | Liver | GSK-4532990 (formerly ARO-HSD) | Phase 2 | GSK | | Fazirsiran | Phase 3 | Takeda and Arrowhead | | JNJ-3989 | Phase 2 | Janssen | | HZN-457 (formerly ARO-XDH) | Phase 1 | Horizon | | ARO-C3 | Phase 1/2 | Arrowhead | | ARO-PNPLA3 (formerly JNJ-75220795) | Phase 1 | Arrowhead | Muscle | ARO-DUX4 | Pre-Clinical | Arrowhead | Central Nervous System (CNS) | ARO-SOD1 | Pre-Clinical | Arrowhead |
|